ASCO 2023 | Addressing treatment options for IDH-mutant gliomas

Karan Dixit, MD, Northwestern Memorial Hospital, Chicago, IL, summarizes the clinical implications of the findings from the INDIGO trial (NCT04164901). This included delaying subsequent treatments in patients usually approached with a wait-and-see strategy. The data collected supports a new standard of care via the addition of a target therapy for patients who have an aggressive form of glioma with few treatment options. Secondly, targeting gliomas with checkpoint inhibitors has clinical impact, and further investigations should focus on the combination of IDH inhibition with various other treatments, such as immunotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.